This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Takes a Flogging

The news didn't bother Michael Krensavage of Raymond James, who told clients that he was keeping a strong buy rating. Even though third-quarter revenue fell by 5%, that was a smaller decline than Krensavage had predicted.

And while Pfizer's third-quarter profit was 51 cents, excluding items, that was 4 cents better than Krensavage had forecast. He doesn't own shares, but his firm says it expects to receive or intends to seek investment-banking compensation from companies mentioned in its research reports.

Meanwhile, James Kelly of Goldman Sachs says his estimates are under review. His research note says he still has an outperform rating on Pfizer. He doesn't own shares, and his firm has had an investment banking relationship with the company.

The Cholesterol Connection

Part of the problem is Lipitor, the anti-cholesterol drug whose U.S. revenue rose just 1% in the quarter due to "an unexpectedly rapid slowdown in the U.S. lipid-lowering market as a whole and marginal Lipitor prescription share erosion during the quarter of one percentage point," the company said.

The company said the rate of growth in new prescriptions in the overall lipid-reducing market was 8% in the third quarter, down from 17% in the first half of the year. Pfizer said its drug still commands 40% of all lipid-lowering prescriptions, well above any competitor.

"We believe that Lipitor is poised for further growth fueled by newly emergent outcomes data, which once again confirm Lipitor's outstanding ability to reduce morbidity associated with cardiovascular disease," Pfizer said. "We believe that these new data will support renewed growth for Lipitor. These data will also be prominently featured in upcoming physician and consumer branded and unbranded promotion beginning this quarter."

Lipitor's foreign-market sales came to the rescue, adding 14% for the quarter. Worldwide Lipitor sales rose 6% to $2.9 billion.
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $32.71 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs